-

Company Profile for HDT Bio Corp.

--(BUSINESS WIRE)--HDT Bio Corp. is bringing immunotherapies to people around the world. With a focus on RNA, formulation, and adjuvant technologies, HDT Bio is developing biotherapeutics for oncology and infectious disease applications. HDT Bio simultaneously works to integrate therapeutic approaches for first-in-class medicines while building on decades of development experience with well-established pharmaceutical ingredients. The resulting products are poised to significantly affect the lives of millions of people worldwide and to provide access to lifesaving therapies for underserved populations. One of the company’s core technologies, RNA/LION, combines formulation and adjuvant ingredients to stabilize and deliver RNA to the immune system to stimulate responses for therapy or vaccination.

Company:

HDT Bio Corp.

 

 

Headquarters Address:

1616 EASTLAKE AVE E

 

SUITE 280

 

SEATTLE, WA 98102

 

 

Main Telephone:

425-241-4152

 

 

Website:

hdt.bio

 

 

Type of Organization:

Private

 

 

Industry:

Biotechnology

 

 

Key Executives:

COO: Christopher Pirie

 

CEO: Steven Reed

 

CSO: Darrick Carter

 

 

COO

 

Contact:

Christopher Pirie

Phone:

425-241-4152

Email:

christopher.pirie@hdt.bio

 

HDT Bio Corp.


Release Versions

More News From HDT Bio Corp.

HDT Bio Doses First Healthy Volunteer in US Phase 1 Trial of Next Generation COVID-19 Variant RNA Vaccine

SEATTLE--(BUSINESS WIRE)--HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, today announced the first healthy volunteer has been dosed in the company’s US Phase 1 clinical trial of its next generation COVID-19 RNA vaccine, HDT-301. The vaccine targets the Beta variant of SARS-CoV-2 and has a demonstrated ability to provide broad protection against multiple variants of the virus that causes COVID-19 and unique cellular immunity compared to existing mRNA vaccines...

Brazil’s SENAI CIMATEC Doses First Healthy Volunteers in Phase 1 trial of HDT Bio’s RNA COVID-19 Vaccine

SEATTLE & SALVADOR, Brazil--(BUSINESS WIRE)--First patient dosed in Brazil with HDT Bio's Covid rna vaccine....

HDT Bio Partners with Brazil’s SENAI CIMATEC to Advance RNA COVID-19 Vaccine to Fight Pandemic

SEATTLE & SALVADOR, Brazil--(BUSINESS WIRE)--HDT Bio Partners with Brazil’s SENAI CIMATEC to Advance RNA COVID-19 Vaccine to Fight Pandemic....
Back to Newsroom